-
Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The presentations will feature data on approved medicines Polivy (polatuzumab vedotin), Lunsumio (mosunetuzumab), and Columvi (glofitamab), including long-term follow-up and…
-
China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment
•
China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its Opzelura (ruxolitinib) cream has been approved in Hong Kong. This topical Janus kinase (JAK) inhibitor is now approved for use as a local treatment for non-segmental vitiligo in patients aged 12 years and above, expanding…
-
Legend Biotech to Showcase CARTITUDE-4 Trial Data on Carvykti at ASH Annual Meeting
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) is set to present new data on minimal residual disease (MRD) negativity rates from the Phase III CARTITUDE-4 trial at the 66th Annual American Society of Hematology (ASH) Annual Meeting in San Diego. The data will compare Carvykti (ciltacabtagene autoleucel; cilta-cel) treatment with the…
-
Shanghai Duoning Biotechnology Partners with Branca Bunús for Transfection Reagents Innovation
•
Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a strategic partnership with Ireland-based Branca Bunús Ltd, a leader in gene delivery technology. This collaboration aims to provide biopharmaceutical customers with innovative transfection reagents through resource sharing, focusing on the development, optimization, and application of…
-
Asieris Pharmaceuticals Receives NMPA Approval for Hexvix (APL-1706) in Bladder Cancer Diagnosis
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that the National Medical Products Administration (NMPA) has approved a marketing filing for its product Hexvix (APL-1706), which is used in the diagnosis and management of bladder cancer. Product Approval and ImpactThe approval of Hexvix by the NMPA marks a…
-
Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy
•
Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for its version of albuvirtide, marking a significant step forward for China’s first domestically developed innovative HIV therapy. The study will evaluate albuvirtide as a maintenance…
-
Fresenius Medical Care Reports 2% YOY Revenue Decrease in 2024 Q3 Financial Results
•
Germany-based Fresenius Medical Care (FRA: FMEA) has released its financial report for the third quarter of 2024. The total revenues for the quarter reached EUR 4.76 billion, marking a year-on-year (YOY) decrease of 2% in constant exchange rate terms. The operating income saw a significant rise, increasing by 43% YOY…
-
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
•
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules…
-
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
•
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year 2024, reporting a 5% year-on-year (YOY) increase in global revenues at constant exchange rates (CER), reaching JPY 2.38 trillion (USD 15.63 billion). The core operating profit margin expanded to 30.2%, marking a 2.2 percentage point…
-
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment
•
US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF),” covers formulations comprising istaroxime and methods of use, either alone or in combination with…
-
BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment
•
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval from China’s National Medical Products Administration (NMPA) for its anti-PD-1 drug Opdivo (nivolumab) in combination with cisplatin and gemcitabine. This approval is for a first-line treatment of unresectable or metastatic urothelial carcinoma (UC). The Opdivo/chemo…
-
Boston Scientific Corporation Announces Acquisition of Cortex, Inc.
•
US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Cortex, Inc., a medical technology company under the Ajax Health umbrella. The financial details of the agreement have not been disclosed, and the transaction is expected to close in the first half of…
-
Legend Biotech Corporation Appoints Alan Bash as President of Carvykti
•
China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has announced the appointment of Alan Bash as the President of Carvykti, a BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy. In this role, Mr. Bash will oversee the continued growth of Carvykti, managing Legend Biotech’s…
-
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
•
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis’ TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary…
-
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
-
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving Loan Facility of up to USD 100 million with HSBC, a leading global bank and financial services institution. This customized financing solution is designed to support the expansion of Insilico’s proprietary novel drug discovery pipeline…
-
Shanghai HeartCare Medical Technology Receives NMPA Approval for Embolization Stent
•
China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) for its innovative intracranial aneurysm embolization assisted stent. This product is now cleared for use in clinical standard interventional surgical settings for intravascular embolization and blood flow reconstruction in patients diagnosed…
-
Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments
•
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. The joint project aims to address the urgent and unmet needs of individuals living with mental health conditions, with a specific focus on developing…
-
HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment
•
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food and Drug Administration (FDA) for its drug candidate HG202, an innovative treatment for neovascular age-related macular degeneration (nAMD). BRIGHT Study to Assess Safety and Tolerability of HG202The upcoming BRIGHT study, an open-label, multicenter dosage escalation…
-
NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System
•
China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology (Suzhou) Co., Ltd. for its knee joint prosthesis system, a significant advancement for domestic medical device innovation. Innovative Design of the Knee Joint Prosthesis SystemThe knee joint prosthesis system, designed for first-time knee replacement surgery…
